Comprehensive Study Guide for Jascade and OFEV Package Inserts

Session Overview and Training Housekeeping

  • The session, designated as Vilt Number 3, is a comprehensive review of the Package Insert (PI) for Jascade and a summary of the OFEV PI.

  • The trainer, Amy, emphasizes that the entirety of the session contains "pearls" for the upcoming Jascade PI exam (scheduled for Tuesday) and the OFEV exam (scheduled for Wednesday).

  • Jascade Exam Details:

    • 25 multiple-choice questions.

    • 45-minute time limit.

    • Passing score requirement: 85%85\%.

  • Teach-back Presentations:

    • These should be no more than 5 minutes5\,minutes.

    • They involve using a few PowerPoint slides or props to teach a high-level concept to someone with no prior knowledge of the topic.

    • Students are encouraged to use the time after the Jascade exam to collaborate with partners on these presentations.

  • Technical Note: The trainer is working with the Viva team to resolve issues regarding missing accounts/providers in the IVA (Interactive Visual Aid) software.

Personal Narrative: Letter to My Lungs

  • Amy and a participant named Robin share personal stories as part of a "Letter to My Lungs" exercise to contextualize the respiratory space.

  • Amy’s Narrative:

    • Developed severe asthma at age three following a pony ride.

    • Inherited "dramatic lungs" from her father, who was relocated from Michigan to Arizona for the climate due to childhood asthma.

    • Experienced treatment with oxygen tents, nebulizers, epinephrine shots, and steroids (which she jokes affected her height).

    • Notes a singular event where a massive asthma attack kept her father home from a business trip on the night a drunk driver killed the four colleagues who went in his place.

    • Spent nearly 20 years20\,years working in the respiratory space to help others with lung issues.

  • Robin’s Narrative:

    • An ex-smoker who grew up in a culture where smoking was expected (New York).

    • Expresses gratitude to her lungs for "covering" for her despite years of smoking cigarettes and marijuana.

    • Highlights the importance of honesty regarding lifestyle choices in the context of respiratory health.

Historical Context of Lung Disease Treatments: OFEV and Esbriet

  • OFEV (Nintedanib):

    • Generic name: Nintedanib.

    • Mnemonic: "No PE" (No = Nintedanib = OFEV).

    • Launched in 20142014.

    • Three Indications:

    1. IPF (Idiopathic Pulmonary Fibrosis).

    2. SSC-ILD (Systemic Sclerosis-associated Interstitial Lung Disease).

    3. Progressive Fibrosing ILD (formerly known as CF-ILD: Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype).

    • Principal side effect: Diarrhea (most severe in the first 3 months3\,months).

  • Esbriet (Pirfenidone):

    • Generic name: Pirfenidone.

    • Mnemonic: "PE" (PE = Pirfenidone = Esbriet).

    • Launched in 20142014 by Genentech.

    • Indications: Only one (IPF).

    • Principal side effect: Photosensitivity (a major concern in sunny climates like Arizona or Florida).

  • Generic Availability: Both Nintedanib and Pirfenidone are now available generically. Some insurance plans require a "step edit," where patients must fail one of these treatments before accessing Jascade.

Jascade (Nerandomolast) Indications and Administration

  • Generic Name: Nerandomolast.

  • Indications (Section 1.1 and 1.2):

    • Treatment of Idiopathic Pulmonary Fibrosis (IPF).

    • Treatment of Progressive Pulmonary Fibrosis (PPF).

  • Dosing (Section 2.1, 2.2, 2.3):

    • Recommended maximum dosage: 18 mg18\,mg orally twice daily (BID\text{BID}, approximately 12 hours12\,hours apart).

    • Reduced dosage: 9 mg9\,mg twice daily if the patient is intolerant or if using specific concomitant medications.

  • Administration Options:

    • Swallowed Whole: Can be taken with or without food.

    • Water Dispersion Method: For patients with difficulty swallowing.

    • Place tablet in a glass with approximately 3−4 ounces3-4\,ounces (90−120 mL90-120\,mL) of room-temperature water.

    • Stir and let sit for 15−20 minutes15-20\,minutes until fully dispersed into small pieces.

    • Drink the mixture within 2 hours2\,hours of preparation.

    • Rinse the glass with an additional 3−4 ounces3-4\,ounces of water and drink immediately to ensure the full dose is consumed.

  • Missed Doses: If a dose is missed, patients should take the next dose at the scheduled time. They should not double the dose to make up for the missed one.

  • Dosage Forms (Section 3): Available as 9 mg9\,mg and 18 mg18\,mg tablets.

  • Warnings and Precautions: There are currently no warnings or precautions listed in the Jascade PI.

Jascade Drug Interactions and Special Populations

  • Pirfenidone (Esbriet) Interaction (Section 7.1):

    • Concomitant use with Pirfenidone decreases the exposure of Nerandomolast.

    • Required dose: Patients on Pirfenidone must take Jascade 18 mg18\,mg BID.

    • Important: Do not reduce the dosage to 9 mg9\,mg BID because efficacy was not observed at the lower dose when combined with Pirfenidone.

  • Strong CYP3A Inhibitors (Section 2.2 and 7.1):

    • Concomitant use with strong CYP3A inhibitors increases Nerandomolast exposure.

    • Recommended Action: Reduce Jascade dosage to 9 mg9\,mg twice daily.

    • Examples: Itraconazole (Sporanox), Ketoconazole, Ritonavir, Clarithromycin, and Grapefruit Juice.

  • Pregnancy (Section 8.1):

    • No available human data to evaluate drug-associated risks for birth defects or miscarriage.

    • Animal data exists, but the drug has not been studied in pregnant humans.

    • There are risks to both mother and fetus if conditions like IPF go untreated during pregnancy.

  • Hepatic Impairment (Section 8.7):

    • Child-Pugh Class A (Mild) and Class B (Moderate): No dosage adjustment required. Dosing remains the same as for patients with normal hepatic function.

    • Child-Pugh Class C (Severe): Not studied; use is likely avoided.

Safety Profile: The Diarrhea Theme

  • Adverse Reactions (Section 6.1):

    • The most frequent adverse reaction leading to treatment discontinuation was diarrhea.

  • FiberNeer IPF Study Discontinuation Rates:

    • Jascade 18 mg18\,mg BID (Without background anti-fibrotics): 1%1\% discontinuation due to diarrhea.

    • Jascade 9 mg9\,mg BID (Without background anti-fibrotics): 0%0\% discontinuation due to diarrhea.

    • Placebo (Without background anti-fibrotics): 0%0\% discontinuation due to diarrhea.

  • Contextual Comparison: While 42%42\% of all-comer patients reported diarrhea as an adverse event (often due to background treatment with Nintedanib), the actual discontinuation rate for Jascade alone is very low (1%1\%).

  • Note on COVID-19: COVID-19 appears on the adverse reaction list in the PI. The drug does not cause COVID; rather, these events occurred and were reported during the global pandemic while the trials were active.

Mechanism of Action (MOA)

  • Classification (Section 12.1): Nerandomolast is an inhibitor of Phosphodiesterase 4 (PDE4).

  • Selectivity: It demonstrates at least a ninefold preferential inhibition of the PDE4B isoenzyme over PDE4A, C, and D based on in-vitro data.

  • Process:

    • PDE4 normally hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP).

    • By inhibiting PDE4 (specifically the B isoenzyme found in the lungs and CNS), Jascade elevates cellular cAMPcAMP levels.

    • This reduction in cAMPcAMP hydrolysis leads to reduced expression of pro-fibrotic growth factors and inflammatory cytokines.

  • Effects: Exerts both anti-fibrotic and immunomodulatory effects.

  • Clinical Significance: Targeting the PDE4B isoenzyme specifically (the "ninefold preference") rather than being a "pan-PDE4" inhibitor helps reduce the physiological "baggage" or side effects typically associated with this drug class (e.g., severe nausea or diarrhea).

Clinical Trials: FiberNeer IPF

  • Primary Endpoint: Absolute change from baseline in Forced Vital Capacity (FVC) in milliliters (mLmL) at 52 weeks52\,weeks.

  • Secondary Endpoint: A composite endpoint consisting of the time to the first occurrence of:

    1. Acute IPF exacerbation.

    2. First hospitalization for respiratory cause.

    3. Death.

  • Numerical Results at 52 Weeks (Adjusted Mean Decline in FVC):

    • Jascade 18 mg18\,mg: −106 mL-106\,mL.

    • Jascade 9 mg9\,mg: −122 mL-122\,mL.

    • Placebo Group: −170 mL-170\,mL.

Clinical Trials: FiberNeer ILD (Progressive Pulmonary Fibrosis)

  • Trial Population: 44%44\% of patients were on stable background treatment with Nintedanib (OFEV); 56%56\% were not on Nintedanib.

  • Definition of Progression (Section 14.2): Patients must have presented with at least two of the following clinical signs within the 24 months24\,months prior to screening:

    1. FVC decline ≥10%\ge 10\%.

    2. FVC decline ≥5%\ge 5\% and <10%< 10\% with worsening of respiratory symptoms or imaging.

    3. Worsening of respiratory symptoms and worsening of imaging.

  • Numerical Results at 52 Weeks (Adjusted Mean Decline in FVC):

    • Jascade 18 mg18\,mg: −86 mL-86\,mL.

    • Jascade 9 mg9\,mg: −69 mL-69\,mL.

    • Placebo Group: −152 mL-152\,mL.

  • Secondary Endpoint: Time to first occurrence of a composite of acute ILD exacerbation, respiratory-cause hospitalization, or death over the blinded duration (up to 109 weeks109\,weeks).

Questions & Discussion

  • Question (Chris): Will the exam require knowing the specific page numbers or paragraph locations?

  • Response (Amy): No, the exam focuses on identifying the information itself, not the physical location in the document.

  • Question (Chris): What is the significance of the ninefold preferential inhibition of PDE4B?

  • Response (Amy): It means the drug is much more specific to inhibiting the B isoenzyme (located in the lungs) rather than A, C, or D. This specificity is why we see improved tolerability and lower rates of gastrointestinal side effects compared to non-selective PDE4 inhibitors.

  • Question (Lisa): Does the dosing change for liver function?

  • Response (Amy): No adjustment is needed for mild or moderate (Child-Pugh A or B) impairment. Severe (Class C) has not been studied.

  • Question (Chris): What is the half-life of Jascade?

  • Response (Amy): Amy initially notes that this is rarely discussed in the field but finds that it takes four days to reach a steady state. She clarifies for OFEV that the half-life is approximately 9.5 hours9.5\,hours. (Note: She pledges to double-check the exact Jascade half-life for the group).

  • Question (Reagan): Are numerical values required for the primary/secondary endpoints?

  • Response (Amy): You need to know what the endpoints are (e.g., absolute change in FVC) and the key result numbers from the trials (e.g., −106 mL-106\,mL vs. −170 mL-170\,mL).